Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

Viking Therapeutics traded as low as $31.00 and last traded at $30.97. 886,719 shares traded hands during trading, a decline of 77% from the average session volume of 3,895,525 shares. The stock ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

Reasons to buy Viking Therapeutics now It's hard to overstate the commercial success of drugs that reduce appetites by acting on glucagon-like peptide-1 (GLP-1) receptors.

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street's major indices kicked off the trading on a positive note ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an average annual return of 34.45%. Currently, Viking Therapeutics has a ...

We recently published an article titled These 10 Companies Led Monday's Downturn. In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other ...